The Quantum FIRST trial randomized 539 young patients, median age of 58 years, with newly diagnosed FLT3-mutated AML to receive “7 + 3” induction chemotherapy followed by high-dose cytarabine (HiDAC) consolidation or consolidative allo-HCT with quizartinib or placebo [55]. This evidence concerns the gene FLT3 and acute myeloid leukemia.